Shares in Novo Nordisk surged 6% Tuesday, after the Wegovy maker secured approval of its GLP-1 capsule — a world first.
The U.S. Meals and Drug Administration’s approval of Novo Nordisk’s GLP-1 capsule offers the Danish pharmaceutical big a head begin over U.S. rival Eli Lilly.
The capsule’s beginning dose of 1.5 milligrams will likely be obtainable in pharmacies and by way of choose telehealth suppliers with financial savings affords for $149 per thirty days in early January, the agency stated.
Money-paying sufferers can entry it for a similar worth by way of President Donald Trump’s direct-to-consumer web site, TrumpRx, in accordance with the deal Novo Nordisk struck together with his administration final month. Drug pricing has been prime of thoughts this 12 months because the U.S. seems to be to cut back the prices paid by customers.
The approval caps a turbulent 12 months for Novo, which has been marked by board drama, provide chain shortages, a bidding conflict in opposition to Pfizer, and criticisms over the execution of its U.S. technique.
— CNBC’s Annika Kim Constantino additionally contributed to this report.